ALLO-647

Phase 2Cell therapy

AAllogene Therapeutics

ALLO-647 is one of 168 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Follicular LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

ALLO-647

AAllogene Therapeutics

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Velban

EEastern Cooperative Oncology Group

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Multiple Myeloma

NCT04093596

Q2 2029

Phase 1/2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT04416984

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·AAllogene Therapeutics·Phase 1/2·NCT05000450·6 enrolled

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Active, not recruiting·AAllogene Therapeutics·Phase 1·NCT04093596·132 enrolled

Chronic Lymphocytic Leukemia1 trial

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruiting·AAllogene Therapeutics·Phase 1/2·NCT04416984·160 enrolled

Follicular Lymphoma1 trial

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Completed·AAllogene Therapeutics·Phase 1·NCT03939026·50 enrolled

Lymphoma1 trial

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Terminated·AAllogene Therapeutics·Phase 2·NCT05714345·2 enrolled

Renal Cell Carcinoma1 trial

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Active, not recruiting·AAllogene Therapeutics·Phase 1·NCT04696731·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ALLO-647. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALLO-647 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALLO-647. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allogene Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: AAllogene Therapeutics

ALLO-647

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2029

Trials by Indication[1]

Multiple Myeloma2 trials

Chronic Lymphocytic Leukemia1 trial

Follicular Lymphoma1 trial

Lymphoma1 trial

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News